Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges

Abstract

Photodynamic therapy (PDT), and sonodynamic therapy (SDT) that developed from PDT, have been studied for decades to treat solid tumors. Compared with other deep tumors, the accessibility of urological tumors (e.g., bladder tumor and prostate tumor) makes them more suitable for PDT/SDT that requires exogenous stimulation. Due to the introduction of nanobiotechnology, emerging photo/sonosensitizers modified with different functional components and improved physicochemical properties have many outstanding advantages in cancer treatment compared with traditional photo/sonosensitizers, such as alleviating hypoxia to improve quantum yield, passive/active tumor targeting to increase drug accumulation, and combination with other therapeutic modalities (e.g., chemotherapy, immunotherapy and targeted therapy) to achieve synergistic therapy. As WST11 (TOOKAD® soluble) is currently clinically approved for the treatment of prostate cancer, emerging photo/sonosensitizers have great potential for clinical translation, which requires multidisciplinary participation and extensive clinical trials. Herein, the latest research advances of newly developed photo/sonosensitizers for the treatment of urological cancers, and the efficacy, as well as potential biological effects, are highlighted. In addition, the clinical status of PDT/SDT for urological cancers is presented, and the optimization of the photo/sonosensitizer development procedure for clinical translation is discussed.

From the Discovery of Targets to Delivery Systems: How to Decipher and Improve the Metallodrugs’ Actions at a Molecular Level

“…This leads to transient arterial vasodilation that then triggers the release of the vasoconstrictor endothelin-1. The rapid consumption of the •NO radicals by oxygen radicals leads to the formation of reactive nitrogen species (e.g., RNS and peroxynitrite), in parallel with arterial constriction [ 89 , 90 ].…”

Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches

“…Although there are no specific studies on the use of PDT and sonodynamic therapy (SDT) for prostate cancer treatment, these therapies are currently being studied for their potential in cancer treatments [ 39 , 84 ]. PDT and SDT utilize sensitizers that can produce ROS, which can cause damage to cancer cell membranes.…”

Ferrous Selenide Stabilized Black Phosphorus Heterojunction Sonosensitizer for MR Imaging-Guided Sonodynamic Therapy of Bladder Cancer

“…Sonodynamic therapy (SDT) is an emerging therapeutic approach that can realize reactive oxygen species (ROS)-inducing apoptosis or necrosis by utilizing the ultrasound (US) to activate the sonosensitizers that accumulate in tumor cells [ 5 – 10 ]. Compared with traditional treatment methods, SDT is considered one of the most efficient non-invasive cancer treatment methods [ 11 , 12 ]. The US could penetrate tens of centimeters of soft tissue without the need for endoscopy or other bladder interventions.…”